Monocyte Subset Identification via HLA-DR Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The traditional study of monocytes as a whole population lacks clarity in clinical diagnosis, and the measurement of CD14+HLA-DRlo/neg monocytes is often subjective and inconsistent, which hampers the accuracy of immunotherapy response prediction and cancer treatment efficacy.
Innovation Solution
A method involving the direct quantification of HLA-DR expression levels on monocyte subsets, specifically classical monocytes, using flow cytometry with fluorescently labeled specific binding members for CD14, CD16, CD192 (CCR2), and HLA-DR, to identify and quantify monocyte subsets accurately.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If monocytes are studied as a whole population, then the analysis is simpler, but the clinical diagnostic clarity is insufficient
Solution Approach 1:
The patent segments monocytes into three distinct subsets (classical CD14++CD16−, intermediate CD14++CD16+, and non-classical CD14+CD16++) based on differential expression of surface markers CD14, CD16, and CCR2. This segmentation allows for precise identification and quantification of each subset, resolving the technical contradiction by maintaining analytical simplicity through standardized gating strategies while achieving enhanced clinical diagnostic clarity through subset-specific characterization.
2Ease of operation
If HLA-DR expression is measured qualitatively, then the measurement is easier, but the quantification is subjective and inconsistent
Solution Approach 1:
The patent transforms the qualitative assessment of HLA-DR expression into a quantitative measurement by establishing standardized fluorescence intensity thresholds and using calibrated beads for absolute quantification. This parameter change from qualitative to quantitative measurement resolves the contradiction by maintaining ease of operation through flow cytometry while achieving consistent and objective quantification across different laboratories and experiments.
3Measurement precision
If multiple markers are used to identify monocyte subsets, then the identification accuracy is improved, but the assay complexity increases
Solution Approach 1:
The patent uses a segmented approach with a panel of four fluorescently labeled antibodies targeting CD14, CD16, CCR2, and HLA-DR to identify and characterize monocyte subsets. This segmentation of the assay into specific marker panels resolves the technical contradiction by achieving high identification accuracy through multi-parameter flow cytometry while managing complexity through standardized gating strategies and comprehensive data analysis algorithms.
4Ease of operation
If HLA-DR expression is measured without calibration, then the measurement process is simpler, but the quantification reliability is reduced
Solution Approach 1:
The patent introduces calibrated fluorescent beads as an intermediary standard to bridge the measurement process and achieve reliable quantification. These beads with known fluorescence intensities serve as a reference to calibrate the flow cytometer and convert relative fluorescence units into absolute HLA-DR molecule counts per cell. This intermediary approach resolves the contradiction by adding a calibration step that maintains operational simplicity while dramatically improving quantification reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a quantitative and consistent method for identifying monocyte subsets, enhancing the specificity and reliability of immunotherapy response prediction and cancer treatment efficacy assessment.
Implementation Method 1
fluorescently labeled specific binding members for CD14, CD16, CD192 (CCR2), and HLA-DR
Data Source
AI summary
Methods of identifying monocyte subsets in a sample are provided. Aspects of the methods include assaying the sample to obtain relative expression level data for each of CD14, CD16, and CD192 (CCR2) and quantitative expression level data for HLA-DR; and employing the obtained data to identify monocyte subsets in the sample. Also provided are compositions and kits for practicing embodiments of the invention. The methods and compositions find use in a variety of different applications, including therapeutic applications.